BAFNAPH vs SYNCOMF: Stock Comparison

BAFNAPH vs SYNCOM FORMU (I)Updated 9 Jun 26, 4:08 PM ISTNSE & company filings

SYNCOM FORMU (I) is the larger company by market capitalisation. BAFNAPH shows a lower P/E and faster revenue growth, while SYNCOM FORMU (I) shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BAFNAPH leads 4; SYNCOMF leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BAFNAPHSYNCOMF

Valuation lens

What price are you paying?

Market CapContext only
₹702 Cr
₹1,933 Cr
P/E RatioBAFNAPH has the lower reading
0x
21.38x
P/B RatioBAFNAPH has the lower reading
0x
4.41x
EPSSYNCOMF has the higher reading
₹0.03
₹0.26
Book ValueContext only
₹40.64
₹4.41
Dividend YieldSame reading
0%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SYNCOMF is the larger company
₹1,933 Cr vs ₹702 Cr
P/E Ratio
BAFNAPH has a lower P/E
0x vs 21.38x
P/B Ratio
BAFNAPH has a lower P/B
0x vs 4.41x
EPS
SYNCOMF has higher earnings per share
₹0.26 vs ₹0.03
Revenue Growth (TTM YoY)
BAFNAPH has faster revenue growth
15.4% vs -9%
EPS Growth (TTM YoY)
BAFNAPH has faster EPS growth
95% vs 68.8%
Qtr Sales Growth
SYNCOMF has stronger quarterly sales growth
0.7% vs -82.35%
Qtr Profit Growth
SYNCOMF has stronger quarterly profit growth
1.05% vs -99.32%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBAFNAPHSYNCOMF
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBAFNAPHSYNCOMF
Live Price₹174.58₹20.58
Day Change-10%-3.65%
Volume2.84 L1.68 Cr
52-Week High₹213.36₹22.59
52-Week Low₹94.77₹10.21
Distance from 52W High-18.18%-8.9%

Valuation

MetricBAFNAPHSYNCOMF
Market Cap₹702 Cr₹1,933 Cr
P/E Ratio0x21.38x
P/B Ratio0x4.41x
EPS₹0.03₹0.26
Book Value₹40.64₹4.41
Dividend Yield0%0%

Growth

MetricBAFNAPHSYNCOMF
Revenue Growth (TTM YoY)15.4%-9%
EPS Growth (TTM YoY)95%68.8%
Qtr Sales Growth-82.35%0.7%
Qtr Profit Growth-99.32%1.05%

Profitability & Leverage

MetricBAFNAPHSYNCOMF
ROE11.54%18.43%
ROCE11.12%18.63%
Net Margin7.37%15.63%
Operating Margin9.71%20.89%
Debt to Equity0.39x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBAFNAPHSYNCOMF
Promoter Holding75%50.57%
FII Holding9.34%0.35% 0.14 pp
DII Holding0%0%
Public Holding15.66%49.08% 0.13 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BAFNAPH and SYNCOM FORMU (I).

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.